News

Apply now for the ATCC Innovation Challenge

ATCC is excited to launch their 2025 Innovation Challenge, inviting researchers to explore bold, creative applications of their ThawReady™ Assay Ready Cells, an innovative line of products  designed to accelerate cell-based assays and eliminate the need for lengthy cell expansion and banking prior to starting bioassays, saving valuable time and money.

Running through November 30, 2025, the challenge offers researchers an opportunity to win free ThawReady™ products and gain visibility through collaboration with ATCC in webinars, conference showcases, and other scientific platforms. To enter, researchers must submit a short proposal (up to 1000 characters) describing how they plan to use ThawReady™ cells in their innovative research. Winning entries will receive complimentary products and the opportunity to share their work with the broader scientific community.

Two models are available for the challenge:

ThawReady™ THP-1 (TIB-202-AR)

  • Derived from a human monocytic leukemia patient.
  • Ideal for immunology, toxicology, and cancer research.
  • Supports assays such as monocyte differentiation, phagocytosis, and co-culture studies.
  • Preserved in a chemically defined, animal-free formulation.
  • Ready to use upon thawing with ≥80% viability.

 ThawReady™ THP-1 NF-κB-Luc2 (TIB-202-NFkB-LUC2-AR)

  • Engineered to express luciferase under NF-κB control.
  • Enables sensitive, quantitative analysis of NF-κB activation.
  • Demonstrates over 200-fold increase in luminescence upon LPS stimulation.
  • Maintains functionality and morphology post-thaw, even after extended rest periods.
  • Suitable for drug screening, pathway analysis, and biocompatibility testing.

 

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …